The effect of combined therapy with statins and levothyroxine on the lipid profile dynamics in patients with a comorbid course of arterial hypertension, type 2 diabetes mellitus and subclinical hypothyroidism
DOI:
https://doi.org/10.24959/cphj.19.1502Keywords:
arterial hypertension, type 2 diabetes mellitus, subclinical hypothyroidism, lipid metabolism, statins, levothyroxineAbstract
To date, there are no sufficiently clear recommendations for the management of patients with the TSH level between the upper limit of the control range and 10.0 mIU/L, and with a high cardiovascular risk (CVR).
Aim. to assess the effect of combined therapy with statins and levothyroxine on the state of lipid metabolism and total CVR in patients with comorbid course of arterial hypertension (AH), type 2 diabetes mellitus (T2DM) and subclinical hypothyroidism (SHT).
Materials and methods. 67 patients aged 44 to 75 years with the stage II AH, T2DM and SHT were included. All patients used statins prior to inclusion in the study. At the TSH level of more than 6.0 μMU/ml levothyroxine was additionally prescribed in individually selected doses from 12.5 to 50 μg/day. Lipid and thyroid metabolism indexes, the concentration of C-reactive protein (CRP) and the tumor necrosis factor-α (TNF-α) were measured by standard methods. The period of observation was 12 months.
Results. Patients with TSH levels of >6.0 μMU/ml, despite statin therapy, have more pronounced dyslipidemia, higher CRP values (p<0.05) and a tendency to increase TNF-α (p>0.05). The additional use of levothyroxine led to a significant decrease in total cholesterol (p=0.011), low-density lipoprotein cholesterol (p=0.025), and a highly significant decrease in CRP and TNF-α (p<0.001).
Conclusions. Combined therapy, including statins and levothyroxine, leads to more significant improvement in the lipid profile than statins without the replacement therapy, a decrease in the signs of systemic inflammation, and, in the aggregate, has a positive effect on the total cardiovascular risk in this category of patients.
References
Shestakova, P. P. (2016). Russkii meditcinskii zhurnal (RMZh), 1, 6–8.
Fadeev, V. V. (2013). Klinicheskaia i eksperimentalnaia tireoidologiia, 9(4), 10–14.
Rodondi, N., den Elzen, W. P. J., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., … Thyroid Studies Collaboration, for the. (2010). Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality. JAMA, 304(12), 1365. https://doi.org/10.1001/jama.2010.1361
Budnevskii, A. V., Kravchenko, A. Ia., Drobysheva, E. S., & Feskova, A. A. (2015). Klinicheskaia meditcina, 93(1), 13–17.
Pearce, E. N. (2012). Update in Lipid Alterations in Subclinical Hypothyroidism. The Journal of Clinical Endocrinology & Metabolism, 97(2), 326–333. https://doi.org/10.1210/jc.2011-2532
Tognini, S., Polini, A., Pasqualetti, G., Ursino, S., Caraccio, N., Ferdeghini, M., & Monzani, F. (2012). Age and Gender Substantially Influence the Relationship Between Thyroid Status and the Lipoprotein Profile: Results from a Large Cross-Sectional Study. Thyroid, 22(11), 1096–1103. https://doi.org/10.1089/thy.2012.0013
Hernández-Mijares, A., Jover, A., Bellod, L., Bañuls, C., Solá, E., Veses, S., … Rocha, M. (2013). Relation between lipoprotein subfractions and TSH levels in the cardiovascular risk among women with subclinical hypothyroidism. Clinical Endocrinology, 78(5), 777–782. https://doi.org/10.1111/cen.12064
Robison, C. D., Bair, T. L., Horne, B. D., McCubrey, R. O., Lappe, D. L., Muhlestein, J. B., & Anderson, J. L. (2014). Hypothyroidism as a risk factor for statin intolerance. Journal of Clinical Lipidology, 8(4), 401–407. https://doi.org/10.1016/j.jacl.2014.05.005
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013). 2013 ETA Guideline: Management of Subclinical Hypothyroidism. European Thyroid Journal, 2(4), 215–228. https://doi.org/10.1159/000356507
Redford, C., & Vaidya, B. (2017). Subclinical hypothyroidism: Should we treat? Post Reproductive Health, 23(2), 55–62. https://doi.org/10.1177/2053369117705058
Biondi, B., Cappola, A. R., & Cooper, D. S. (2019). Subclinical Hypothyroidism. JAMA, 322(2), 153. https://doi.org/10.1001/jama.2019.9052
Razvi, S., Weaver, J. U., Butler, T. J., & Pearce, S. H. S. (2012). Levothyroxine Treatment of Subclinical Hypothyroidism, Fatal and Nonfatal Cardiovascular Events, and Mortality. Archives of Internal Medicine, 172(10). https://doi.org/10.1001/archinternmed.2012.1159
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., … Zannad, F. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 31(7), 1281–1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., … Matthews, D. R. (2014). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441
McQuade, C., Skugor, M., Brennan, D. M., Hoar, B., Stevenson, C., & Hoogwerf, B. J. (2011). Hypothyroidism and Moderate Subclinical Hypothyroidism Are Associated with Increased All-Cause Mortality Independent of Coronary Heart Disease Risk Factors: A PreCIS Database Study. Thyroid, 21(8), 837–843. https://doi.org/10.1089/thy.2010.0298
Nemtsova, V., Bilovol, O., Shalimova, A. (2019). Vascular endothelial growth factor as a marker of endothelial dysfunction in poly- and comorbidity: focus on hypertension, type 2 diabetes mellitus and subclinical hypothyroidism. Arterial Hypertension, 23(2), 98–104. https://doi.org/10.5603/AH.a2019.0006
Stryuk, R. I., Sviridova, M. I., Mkrtumyan, A. M., Golikova, A. A. (2016). Klinicheskaya meditsina, 94, 683–687.
Krysiak, R., Gilowski, W., & Okopien, B. (2015). Different Effects of Atorvastatin on Metabolic and Cardiovascular Risk Factors in Hypercholesterolemic Women with NormalThyroid Function and Subclinical Hypothyroidism. Experimental and Clinical Endocrinology & Diabetes, 123(03), 182–186. https://doi.org/10.1055/s-0034-1396886
Rymar, O. D., Mustafina, S. V., Malyshenko, Iu. A. (2012). Ateroskleroz, 2, 32–38.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
